바카라 게임

Regeneron, a globally renowned biotech leader, has built a legacy through its distinctive “new drug-only” business model. At its core lies the VelocImmune platform, a humanized mouse 바카라 게임 instrumental in developing blockbuster drugs. This innovation underscores the potential of fully human antibodies, produced via transgenic mouse platforms, to deliver superior biophysical properties and reduced immune responses. However, the steep barriers to developing such technologies leave South Korean companies questioning whether the dream of a “K-Regeneron” is within reach.

To explore this challenge, HitNews engaged in an in-depth discussion with Chang-gyu Oh, CEO of HuMab, a South Korean biotech developing SynThese, a next-generation 바카라 게임ized transgenic mouse platform. Our follow-up conversation delved deeper into the platform’s potential and its implications for the future of antibody therapeutics.

“There are several reasons why developing 바카라 게임 antibody platforms in Korea is difficult. First, the facilities and specialized personnel required to create transgenic (Tg) mice are limited. Even Regeneron took approximately 14 years to complete its 바카라 게임ized mouse platform, and in Korea, long development timelines and large-scale investments are often challenging to sustain. Additionally, second-generation 바카라 게임 antibody transgenic mouse technologies are tied up in patents held by companies like Regeneron. While attempts to circumvent these patents exist, they often face significant hurdles at the commercialization stage.”

“We classify 바카라 게임 antibody transgenic mice into first, second, and third generations based on the technological advancements in their development.

The first and second generations both utilize microbial genome vectors, such as BAC or YAC, to cut and insert fragments of 바카라 게임 genes. From the inserted library, clones containing 바카라 게임 antibody genes are identified and introduced into mouse embryonic stem (ES) cells.

The first generation involves random insertion of BAC/YAC clones containing only parts of 바카라 게임 antibody genes into mouse cells. This results in recombination occurring only in specific gene segments, leading to a relatively low probability of producing fully 바카라 게임 antibodies. In contrast, the second generation employs targeting techniques to insert the majority of 바카라 게임 antibody gene V-(D)-J regions precisely at the location of mouse antibody genes. This allows for more accurate generation of 바카라 게임 antibodies.

The third generation, developed with our proprietary ‘AiCE’ 바카라 게임, represents a completely new approach that bypasses existing patents. This innovative method sets it apart from earlier generations.”

“HuMab’s AiCE 바카라 게임 is a large-scale genome editing technique capable of ‘interchromosomal replacement editing.’ When applied to human antibody genes, the process begins by marking the desired antibody genes in human donor cells with recombination (loxP) sequences. These donor cells are then isolated as microcells.

Next, the isolated microcells are fused with mouse ES cells that also have the targeted replacement region marked with recombination sequences. This prepares the 바카라 게임 antibody genes for insertion and replacement.

Within the fused cells, Cre proteins target the loxP sequences, enabling the insertion of human genes at specific locations within the mouse genome. Additionally, the mouse genome to be edited is marked with loxP sequences at the same location, ensuring a precise replacement and insertion process. This approach significantly enhances the accuracy of gene insertion compared to traditional random insertion methods, making it a core differentiator of AiCE 바카라 게임.

While conventional BAC-based methods require dozens of targeting steps, 바카라 게임 achieves the same results with just four replacements. This innovation is expected to reduce development timelines from 10 years to 4 years and significantly cut costs.”

“With traditional BAC-based technologies, the 바카라 게임 gene alleles are inevitably homo-allelic, which limits 바카라 게임 diversity. While it is technically possible to create a hetero-allelic structure using existing methods, it requires building a completely new library from scratch, demanding substantial time and resources.

In contrast, our AiCE 바카라 게임 does not rely on BAC libraries but instead utilizes chromosomes from human-derived donor cells. By consecutively using different donor cells, gene editing for hetero-allelic structures becomes feasible. For example, we can use fibroblast cells derived from a Caucasian donor and an Asian donor as separate donor cells to replace and insert different gene chromosomes. This approach enables the creation of hetero mice, resulting in transgenic mice with a significantly higher level of antibody diversity—a level that is difficult to achieve with conventional methods.”

“Phage display is a technique where a diverse library of 바카라 게임 sequences is expressed on the surface of bacteriophages, and specific antibodies that bind to a target antigen are selected through a process called biopanning. While this method is fast and efficient in the initial stages, maintaining binding affinity and stability during later optimization phases can be challenging. Additionally, antibodies with suboptimal biophysical properties, such as hydrophobicity or poor molecular interactions, are frequently encountered.

In contrast, 바카라 게임 antibody transgenic mice eliminate these limitations through natural selection in a biological environment. When B cells are exposed to antigens, they undergo a maturation process during which antibody genes are recombined. This random recombination process naturally leads to the apoptosis of B cells with poor biophysical properties or low antigen-binding affinity. As a result, the surviving B cells produce antibodies with high binding affinity and superior biophysical properties.

바카라 게임 antibody transgenic mice leverage this natural selection process in vivo, allowing for the identification of the highest-quality antibodies. Consequently, this approach produces antibodies with a higher likelihood of clinical success compared to those generated through phage display.”

“We consider ourselves competitors to 바카라 게임. We’re developing new technologies that go beyond their patents. Although we’re still a small venture company, inspired by 바카라 게임’s successful model, we aspire to create new possibilities as ‘K-바카라 게임’ (laughs).”

In summary, HuMab’s journey is not just about following the footsteps of global leaders but about developing innovative and differentiated technologies to explore new opportunities. While their 바카라 게임 is still in progress, its potential and vision are clear. As we look forward to the realization of the “K-Regeneron” dream, we will watch with interest as they piece together this new chapter in biotech history.